



Date: 12/09/2023

BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai – 400 001 Script Code : 539872	National Stock Exchange of India Limited 5 th Floor, Exchange Plaza, Bandra Kurla Complex Bandra (East) Mumbai-400051 Script Code : BAJAJHCARE
--	---

Dear Sir,

Sub : Business Updates- Appointment of Dr. Mohammed Jaweed Mukarram as an Advisor in the Research and Development division, specializing in Active Pharmaceutical Ingredients (APIs).

In terms of regulation 30 of SEBI (LODR) Regulations, 2015, please find attached herewith business updates - Appointment of Dr. Mohammed Jaweed Mukarram as an Advisor in the Research and Development division, specializing in Active Pharmaceutical Ingredients (APIs).

Kindly take the same on record.

Thanking you,

**For and on behalf of Board of Directors of
Bajaj Healthcare Limited**

**Aakash Keshari
Company Secretary**

Encl: a/a

BAJAJ HEALTHCARE LIMITED

Registered Office: 602-606, Bhoomi Velocity Infotech Park, Plot No: B-39, B-39A, B-39A/1, Road No. 23, Wagle Ind. Estate, Thane (West), Thane - 400604

Tel. : + 91 22 66177400/ 401; Fax : +91 22 66177458; E-mail : bajajhealth@bajajhealth.com

CIN No. L99999MH1993PLC072892



CIN: L99999MH1993PLC072892

Registered Office: 602-606, Bhoomi Velocity Infotech Park, Plot No. B-39, B-39A, B-39 A/1,
Rd No.23, Wagle Ind. Estate Thane West, Mumbai – 400604.

Business Update

Bajaj Healthcare Limited (“BHL”) announces the appointment of Dr. Mohammed Jaweed Mukarram as an Advisor in the Research and Development division, specializing in Active Pharmaceutical Ingredients (APIs).

Thane, 12th September, 2023: Bajaj Healthcare Limited (BHL), a leading manufacturer of APIs, Intermediates and Formulations, has announced the appointment of Dr. Mohammed Jaweed Mukarram as an Advisor in the Research and Development division, specializing in Active Pharmaceutical Ingredients (APIs).

BHL is pleased to inform that, the Company has appointed Dr. Mohammed Jaweed Mukarram as an Advisor in the Research and Development division, specializing in Active Pharmaceutical Ingredients (APIs). He is holding 45 years of Research Experience (including Ph.D as well as of post Doctoral). His extensive knowledge and expertise make him a valuable addition to our team.

Commenting on the above business update, Mr. Anil Jain, Joint Managing Director, Bajaj Healthcare said: “I am delighted to inform you that the Company has appointed Dr. Mohammed Jaweed Mukarram as an Advisor in the Research and Development division, specializing in Active Pharmaceutical Ingredients (APIs). Dr. Mohammed Jaweed Mukarram brings with him a wealth of experience spanning an impressive 45 years in the field of Research and Development (including Ph.D as well as of post Doctoral). His extensive knowledge and expertise make him a valuable addition to our team.

Dr. Mohammed Jaweed Mukarram, holds both a Ph.D. and a post-Doctoral degree, underscoring his deep academic background and his commitment to advancing the field. With his remarkable credentials, we are confident that he will play a pivotal role in driving our research initiatives forward.

Dr. Mohammed Jaweed Mukarram, illustrious career includes significant roles at esteemed organizations, such as Sr. Associate Director at Wockhardt, where he spearheaded the Chemical Research Division. Over the years, he has made a mark in the industry by filing a noteworthy 156 patent applications. His expertise has led to the successful handling of over 70 bulk drugs and intermediates, boasting an impressive 35 US Drug Master File (DMF) filings to date.”

About Bajaj Healthcare Limited

Bajaj Healthcare Limited a leading manufacturer of APIs, Intermediates and Formulations established in the year 1993. It specializes in manufacturing of Intermediates, API, formulations & Nutraceuticals. The company has state-of-art manufacturing facilities, dedicated to APIs, Intermediates and formulation. These facilities are designed to meet the requirements of both advanced as well as emerging market opportunities. BHL has a strong presence globally in countries like Europe, USA, Australia, Africa, Middle East and South America.

For further information on the Company, please visit www.bajajhealth.com

Rupesh Nikam (CFO)

Bajaj Healthcare Limited

Contact: +91 22 6617 7400

Email: investors@bajajhealth.com

Disclaimer:

CERTAIN STATEMENTS IN THIS DOCUMENT MAY BE FORWARD LOOKING STATEMENTS. SUCH FORWARD-LOOKING STATEMENTS ARE SUBJECT TO CERTAIN RISKS AND UNCERTAINTIES LIKE GOVERNMENT ACTIONS, LOCAL POLITICAL OR ECONOMIC DEVELOPMENTS, TECHNOLOGICAL RISKS, AND MANY OTHER FACTORS THAT COULD CAUSE OUR ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTEMPLATED BY THE RELEVANT FORWARD-LOOKING STATEMENTS. BAJAJ HEALTHCARE LTD WILL NOT BE IN ANY WAY RESPONSIBLE FOR ANY ACTION TAKEN BASED ON SUCH STATEMENTS AND UNDERTAKES NO OBLIGATION TO PUBLICLY UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT SUBSEQUENT EVENTS OR CIRCUMSTANCE